Pancreatic neuroendocrine tumor accompanied with multiple liver metastases.

作者: Tomohide Hori , Kyoichi Takaori , Shinji Uemoto

DOI: 10.4254/WJH.V6.I8.596

关键词:

摘要: Pancreatic neuroendocrine tumor (P-NET) is rare and slow-growing. Current classifications predict its prognosis postoperative recurrence. Curative resection ideal, although often difficult, because over 80% of patients have unresectable multiple liver metastases extrahepatic metastasis. Aggressive surgery for important to improve survival. or cytoreductive indicated reduce hormone levels symptoms prognosis. Liver transplantation was originally conceived as an ideal therapy metastases. Unfortunately, there no clear consensus on the role timing primary Surgeons still face questions in deciding best surgical scenario with P-NET

参考文章(31)
Emilie Gregoire, Yves Patrice Le Treut, Liver transplantation for primary or secondary endocrine tumors. Transplant International. ,vol. 23, pp. 704- 711 ,(2010) , 10.1111/J.1432-2277.2010.01110.X
Eliano Bonaccorsi-Riani, Carlos Apestegui, Anne Jouret-Mourin, Christine Sempoux, Pierre Goffette, Olga Ciccarelli, Ivan Borbath, Catherine Hubert, Jean François Gigot, Ziad Hassoun, Jan Lerut, Liver transplantation and neuroendocrine tumors: lessons from a single centre experience and from the literature review Transplant International. ,vol. 23, pp. 668- 678 ,(2010) , 10.1111/J.1432-2277.2010.01086.X
Ebrahim S. Delpassand, Amin Samarghandi, Sara Zamanian, Edward M. Wolin, Mohammadali Hamiditabar, Gregory D. Espenan, Jack L. Erion, Thomas M. O’Dorisio, Larry K. Kvols, Jaime Simon, Robert Wolfangel, Arthur Camp, Eric P. Krenning, Alireza Mojtahedi, Peptide receptor radionuclide therapy with 177Lu-DOTATATE for patients with somatostatin receptor-expressing neuroendocrine tumors: the first US phase 2 experience. Pancreas. ,vol. 43, pp. 518- 525 ,(2014) , 10.1097/MPA.0000000000000113
Andreas Pascher, Jochen Klupp, Peter Neuhaus, Transplantation in the management of metastatic endocrine tumours Best Practice & Research in Clinical Gastroenterology. ,vol. 19, pp. 637- 648 ,(2005) , 10.1016/J.BPG.2005.03.008
John G. Touzios, James M. Kiely, Susan C. Pitt, William S. Rilling, Edward J. Quebbeman, Stuart D. Wilson, Henry A. Pitt, Neuroendocrine hepatic metastases: does aggressive management improve survival? Annals of Surgery. ,vol. 241, pp. 776- 785 ,(2005) , 10.1097/01.SLA.0000161981.58631.AB
R. Bettini, W. Mantovani, L. Boninsegna, S. Crippa, P. Capelli, C. Bassi, A. Scarpa, P. Pederzoli, M. Falconi, Primary tumour resection in metastatic nonfunctioning pancreatic endocrine carcinomas. Digestive and Liver Disease. ,vol. 41, pp. 49- 55 ,(2009) , 10.1016/J.DLD.2008.03.015
Paschalis Chatzipantelis, Panagiotis Konstantinou, Michalis Kaklamanos, George Apostolou, Charitini Salla, The role of cytomorphology and proliferative activity in predicting biologic behavior of pancreatic neuroendocrine tumors Cancer Cytopathology. ,vol. 117, pp. 211- 216 ,(2009) , 10.1002/CNCY.20025
Marianne Pavel, Eric Baudin, Anne Couvelard, Eric Krenning, Kjell Öberg, Thomas Steinmüller, Martin Anlauf, Bertram Wiedenmann, Ramon Salazar, ENETS Consensus Guidelines for the management of patients with liver and other distant metastases from neuroendocrine neoplasms of foregut, midgut, hindgut, and unknown primary. Neuroendocrinology. ,vol. 95, pp. 157- 176 ,(2012) , 10.1159/000335597
Marc Kalinowski, Miriam Dressler, Alexander König, Michael El-Sheik, Anja Rinke, Helmut Höffken, Thomas M. Gress, Rudolf Arnold, Klaus-Jochen Klose, Hans-Joachim Wagner, Selective internal radiotherapy with Yttrium-90 microspheres for hepatic metastatic neuroendocrine tumors: a prospective single center study. Digestion. ,vol. 79, pp. 137- 142 ,(2009) , 10.1159/000209849